Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jvs.2016.02.020 http://scihub22266oqcxt.onion/10.1016/j.jvs.2016.02.020 C4925242!4925242!27106243     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Vasc+Surg 2016 ; 64 (1): 46-54.e8 Nephropedia Template TP {{tp|p=27106243|t=2016. Metformin treatment status and abdominal aortic aneurysm disease progression |pdf=|usr=}}{{27106243}} gab.com Text Metformin treatment status and abdominal aortic aneurysm disease progression JO: J Vasc Surg http://www.kidney.de/pget.php?&tw=1&pmid=27106243 #FOAvip Objectives: In population-based studies performed on multiple continents over the past two decades, diabetes mellitus has been negatively associated with the prevalence and progression of abdominal aortic aneurysm (AAA) disease. We investigated the possibility that metformin, the primary oral hypoglycemic agent in use worldwide, may influence the progression of AAA disease Methods: Pre-operative AAA patients with diabetes were identified from an institutional database. After tabulating individual cardiovascular and demographic risk factors and prescription drug regimens, odds ratios for categorical influences on annual AAA enlargement were calculated via nominal logistical regression. Experimental AAA modeling experiments were subsequently performed in normoglycemic mice to validate the database-derived observations, as well as suggest potential mechanisms of metformin-mediated aneurysm suppression. Results: Fifty eight patients met criteria for study inclusion. Of 11 distinct classes of medication considered, only metformin usage was negatively associated with AAA enlargement. This association remained significant after controlling for gender, age, cigarette smoking status and obesity. The median enlargement rate in AAA patients not taking oral diabetic medication was 1.5 mm/year; by nominal logistic regression, metformin, hyperlipidemia, and age ?70 years were associated with below median enlargement, whereas sulfonylurea therapy, initial aortic diameter ?40 mm and statin usage were associated with above median enlargement. In experimental modeling, metformin dramatically suppressed the formation and progression, with medial elastin and smooth muscle preservation and reduced aortic mural macrophage, CD8 T cell and neovessel density. Conclusions: Epidemiologic evidence of AAA suppression in diabetes may be attributable to concurrent therapy with the oral hypoglycemic agent metformin. Twit Text FOAVip Metformin treatment status and abdominal aortic aneurysm disease progression ????J Vasc Surg http://www.kidney.de/pget.php?&tw=1&pmid=27106243 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27106243 #FOAvip English Wikipedia <ref>{{Cite pmid|27106243}}</ref> Metformin treatment status and abdominal aortic aneurysm disease progression #MMPMID27106243 Fujimura N; Xiong J; Kettler EB; Xuan H; Glover KJ; Mell MW; Xu B; Dalman RL J Vasc Surg 2016[Jul]; 64 (1): 46-54.e8 PMID27106243show ga Objectives: In population-based studies performed on multiple continents over the past two decades, diabetes mellitus has been negatively associated with the prevalence and progression of abdominal aortic aneurysm (AAA) disease. We investigated the possibility that metformin, the primary oral hypoglycemic agent in use worldwide, may influence the progression of AAA disease Methods: Pre-operative AAA patients with diabetes were identified from an institutional database. After tabulating individual cardiovascular and demographic risk factors and prescription drug regimens, odds ratios for categorical influences on annual AAA enlargement were calculated via nominal logistical regression. Experimental AAA modeling experiments were subsequently performed in normoglycemic mice to validate the database-derived observations, as well as suggest potential mechanisms of metformin-mediated aneurysm suppression. Results: Fifty eight patients met criteria for study inclusion. Of 11 distinct classes of medication considered, only metformin usage was negatively associated with AAA enlargement. This association remained significant after controlling for gender, age, cigarette smoking status and obesity. The median enlargement rate in AAA patients not taking oral diabetic medication was 1.5 mm/year; by nominal logistic regression, metformin, hyperlipidemia, and age ?70 years were associated with below median enlargement, whereas sulfonylurea therapy, initial aortic diameter ?40 mm and statin usage were associated with above median enlargement. In experimental modeling, metformin dramatically suppressed the formation and progression, with medial elastin and smooth muscle preservation and reduced aortic mural macrophage, CD8 T cell and neovessel density. Conclusions: Epidemiologic evidence of AAA suppression in diabetes may be attributable to concurrent therapy with the oral hypoglycemic agent metformin. äMetformin treatment status and abdominal aortic aneurysm disease progr(epmc).pdf DeepDyve Pubget Overpricing